Kuros News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

07:00	Kuros Biosciences Expands into Extremities Markets (EQS Group)
25.06.24	Kuros Biosciences Announces Peer-Reviewed Publication of MagnetOs MAXA Level 1 Study Outcomes in Spine, Indicating Superiority Over Autograft (EQS Group)
17.04.24	Annual General Meeting of Kuros Biosciences approves all resolutions (EQS Group)
08.03.24	Kuros Biosciences to Report Full Year Financial Results for 2023 and Provide Corporate Update (EQS Group)
01.02.24	Kuros Biosciences to Present at the CG 2024 Musculoskeletal Conference (EQS Group)
31.01.24	Kuros Biosciences Receives US FDA 510K Clearance for MagnetOs Granules for Interbody Use and Regulatory Clearance of MagnetOs Granules and MagnetOs Putty in New Zealand (EQS Group)
04.01.24	Kuros Biosciences Announces Three Advancements Related to its MagnetOsTM Portfolio Including Impressive Fusion Data from MAXA Prospective Randomized Clinical Trial and Two 510(k) Clearances from FDA (EQS Group)
28.11.23	Kuros Biosciences Receives FDA Clearance for Use of MagnetOs in Interbody Spinal Cages (EQS Group)
13.07.23	Kuros Biosciences Announces Completion of Enrollment in the Fibrin-PTH Phase 2 Trial (EQS Group)
21.02.23	Kuros Biosciences Announces Publication of Supportive Osteoimmunology Data for MagnetOs Bone Graft (EQS Group)
23.11.22	Kuros Biosciences Completes Enrollment of Randomized Stage of Phase 2 Trial for Fibrin-PTH (EQS Group)
02.11.22	Kuros Biosciences completes enrolment in Level 1 clinical study of MagnetOs Granules (EQS Group)
19.10.22	Kuros Biosciences awarded 2022 Spine Technology Award for MagnetOs Flex Matrix by Orthopedics This Week (EQS Group)
11.10.22	Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting (EQS Group)
11.10.22	Kuros Biosciences to present positive clinical data for MagnetOs at NASS 2022 Annual Meeting (EQS Group)
23.08.22	Kuros Biosciences MagnetOs Bone Graft Successfully Achieves Three Key Milestones (EQS Group)
31.05.22	Kuros Biosciences announces favorable preliminary results of MagnetOs as standalone alternative to autograft in first randomized controlled trial (EQS Group)
18.05.22	Kuros Biosciences announces commercial launch of MagnetOs Easypack Putty in the U.S. (EQS Group)
03.02.22	Kuros Biosciences's MagnetOs Granules cleared by FDA for expanded spinal indications (EQS Group)
20.01.22	Kuros Biosciences publishes first-in-human clinical data for Fibrin-PTH (KUR-113) in treatment of open tibial shaft fractures (EQS Group)
19.04.21	Annual General Meeting of Kuros Biosciences approves majority of resolutions (Tensid)
13.04.21	Kuros Biosciences treats first patient in clinical trial of MagnetOs Putty; for posterolateral spine fusion (Tensid)
08.04.21	Kuros Biosciences announces treatment of first patient in Australia with MagnetOs for spine fusion (Tensid)
06.04.21	Kuros to receive $2 million milestone payment from Checkmate Pharmaceuticals (Tensid)
29.03.21	Kuros Biosciences publishes invitation to the Annual General Meeting 2021 (Tensid)
18.03.21	Kuros Biosciences reports results for the full year 2020 (Tensid)
10.03.21	Kuros Biosciences to present at upcoming clinical and investor conferences (Tensid)
02.03.21	Kuros Biosciences announces MagnetOs sales and distribution agreements across Northern Europe (Tensid)
20.11.20	Kuros Biosciences wins 2020 Spine Technology Award from Orthopedics This Week (Tensid)
20.10.20	Kuros announces final result of capital increase – total gross proceeds of CHF 18.6 million raised (Tensid)
19.10.20	Kuros announces results of Rights Offering (Tensid)
15.10.20	Kuros provides an update on the planned Capital Increase (Tensid)
06.10.20	Kuros Biosciences to present new data on the role of osteoimmunology in bone formation at NASS 2020 Annual Meeting (Tensid)
05.10.20	Kuros announces all agenda items were approved at its Extraordinary General Meeting today and launches a discounted rights offering expected to raise up to CHF 15.2 million of gross proceeds (Tensid)
05.10.20	Kuros Biosciences reports MagnetOs products approved in Australia (Tensid)
01.10.20	Kuros Biosciences Hosts an Expert Perspectives Webinar on Pioneering Solutions for Targeted and Controlled Bone Healing (Tensid)
21.09.20	Kuros reaches milestone of 2,000 patients treated with MagnetOs bone graft (Tensid)
11.09.20	Kuros Convenes Extraordinary General Meeting (Tensid)
09.09.20	Kuros Biosciences’s licensee Checkmate Pharmaceuticals completes its IPO on NASDAQ (Tensid)
01.09.20	Kuros Biosciences Announces Treatment of the First Patient in its; Spinal Fusion Trial with Fibrin-PTH (Tensid)
12.08.20	Kuros Biosciences Reports Results for First Half 2020 (Tensid)
22.07.20	Kuros Biosciences further strengthens orthobiologics patent portfolio (Tensid)
21.04.20	Annual General Meeting of Kuros Biosciences approves all resolutions (Tensid)
26.03.20	Kuros Biosciences reports results for the full year 2019 (Tensid)
18.03.20	Kuros strengthens orthobiologics patent portfolio (Tensid)
30.01.20	Kuros reports publication of MagnetOs preclinical data demonstrating superiority to market-leading synthetic bone grafts in spinal fusion (Tensid)
03.12.19	Kuros announces final result of Capital Increase – total gross proceeds of CHF 12.5 million raised (Tensid)
02.12.19	Kuros announces results of Rights Offering (Tensid)
29.11.19	Kuros provides an update on the Capital Increase (Tensid)
19.11.19	Extraordinary General Meeting of Kuros Biosciences approves all resolutions (Tensid)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

16:23		Kuros-Aktie gewinnt deutlich: Kuros expandiert in neue Märkte
15:58		Dienstagshandel in Zürich: SPI verbucht nachmittags Abschläge
12:26		Schwacher Handel: SPI notiert am Mittag im Minus
18.11.24		Pluszeichen in Zürich: SPI zum Ende des Montagshandels im Plus
18.11.24		SPI aktuell: SPI nachmittags mit Abgaben
18.11.24		Handel in Zürich: SPI verbucht Verluste
15.11.24		Minuszeichen in Zürich: SPI zum Handelsende leichter
15.11.24		Minuszeichen in Zürich: So entwickelt sich der SPI am Nachmittag

16:23

Kuros-Aktie gewinnt deutlich: Kuros expandiert in neue Märkte

15:58

Dienstagshandel in Zürich: SPI verbucht nachmittags Abschläge

12:26

Schwacher Handel: SPI notiert am Mittag im Minus

18.11.24

Pluszeichen in Zürich: SPI zum Ende des Montagshandels im Plus

18.11.24

SPI aktuell: SPI nachmittags mit Abgaben

18.11.24

Handel in Zürich: SPI verbucht Verluste

15.11.24

Minuszeichen in Zürich: SPI zum Handelsende leichter

15.11.24

Minuszeichen in Zürich: So entwickelt sich der SPI am Nachmittag

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Lonza Grp	515.00	1.42 %	K V
Givaudan	3’857.00	1.15 %	K V
Swiss Re	125.20	0.16 %	K V
Kuehne+Nagel Int	210.50	0.05 %	K V
Holcim	88.28	-0.09 %	K V
Part Grp Hldg	1’209.00	-1.47 %	K V
Logitech Intl	68.68	-1.55 %	K V
CieFinRichemont	118.90	-1.94 %	K V
Nestle	76.52	-2.12 %	K V
Sonova Hldg	298.90	-5.68 %	K V

Nachrichten zu Kuros (Kuros Biosciences)

Aktien Top/Flop

Kuros Peer Group Nachrichten

Meistgelesene Nachrichten